Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Initial public offerings scheduled to debut next week
New York • The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT (www.renaissancecapital.com) and SEC filings.
Week of June 30:
Ambrx Inc. - La Jolla, Calif., 5.4 million shares, priced $12 to $14, managed by Stifel and Wells Fargo. Proposed Nasdaq symbol AMBX. Business: Clinical stage biotech developing optimized protein therapeutics known as bio-conjugates.
GlobeImmune Inc. - Louisville, Colo., 1.6 million shares, priced $15 to $17, managed by Aegis Capital. Proposed Nasdaq symbol GBIM. Business: Developing therapeutic drugs for pancreatic cancer and hepatitis B and C. Previously withdrew in October 2013.
Investar Holding - Baton Rouge, La., 2.9 million shares, priced $15 to $17, managed by Sandler O'Neill and Sterne Agee. Proposed Nasdaq symbol ISTR. Business: Commercial bank in Louisiana with 10 branches.
KineMed Inc. - Emeryville, Calif., 4.5 million shares, priced $6.50 to $7.50, managed by Feltl & Co. Proposed Nasdaq symbol KNMD. Business: Develops Biomarker tests to measure the progression of diseases.
Microlin Bio Inc. - New York, 6 million shares, priced $4.50 to $5.50, managed by Brean Capital and Summer Street Research. Proposed Nasdaq symbol MCLB. Business: Development stage diagnostic and therapeutics company focusing on microRNA and its role in oncology. Shares were increased and range lowered since week of June 16 to 20. Issue was previously postponed.
Minerva Neurosciences Inc. - Cambridge, Mass., 5.5 million shares, priced $10 to $12, managed by Jefferies. Proposed Nasdaq symbol NERV. Business: Clinical stage biotech developing treatments for CNS diseases.
Taggares Agriculture Corp. - Kennewick, Wash., 7 million shares, priced $6 to $7, managed by Janney Montgomery Scott and Roth Capital. Proposed Nasdaq symbol TAG. Business: Operates vineyards and apple orchards in Pacific Northwest.
Note: All issues below except Investar Holding were scheduled to price either last week or the prior week and have not priced or postponed.